Eli Lilly (LLY)

Zepbound vials will be offered for pick-up at Walmart pharmacies nationwide by mid-November.

It offers compelling weight-loss drugs -- and a compelling stock price, too.

This stock has caught fire after some recent events, but how long will that last?

Global pharmaceutical company Eli Lilly (NYSE:LLY) will be announcing earnings results this Thursday before market open. Here’s what investors should know.

This momentary pullback represents an excellent opportunity to buy this high-flying stock.

The Nvidia-powered system aims to cut drug development times and boost innovation.

Shares of leading designer of graphics chips Nvidia (NASDAQ:NVDA) jumped 5.2% in the afternoon session after CEO Jensen Huang laid out an overwhelmingly bullish case for the company's future at a landmark GTC keynote in Washington, D.C. 

Shares of oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) jumped 1.1% in the morning session after it reported third-quarter 2025 results where revenue beat Wall Street's expectations. 

Texas Attorney General Ken Paxton sued Johnson & Johnson and Kenvue, alleging Tylenol was deceptively marketed as safe for pregnant women.

These two have been neglected by Wall Street too much.

Eli Lilly (LLY) is a top growth momentum stock with accelerating earnings, strong technical ratings, and a positive breakout setup for investors.

As the closing bell rings on October 27, 2025, the S&P 500 Healthcare sector stands at a critical juncture, exhibiting the nuanced volatility that defines this essential yet complex segment of the market. While specific daily performance metrics remain unreleased, today's trading likely saw the sector reacting to a

BDF-GESTION Trims Its Eli Lilly (LLY) Stake by 4,149 Shares

This pharma giant is entering the rapidly expanding market for weight loss drugs.

Lilly's stock has pulled back from its 2024 highs, but that doesn't mean the shares are cheap enough to buy.

Long-term investors don't need to rush to buy Eli Lilly stock.

Avidity Biosciences (NASDAQ: RNA) shares soar as Novartis (NYSE: NVS) agrees to acquire them for $12 billion in cash.

The clinical-stage biotech is working on a new type of weight management drug.

Eli Lilly stock rises as $12.47-per-share Adverum Biotech deal boosts its gene therapy ambitions and expands ophthalmology pipeline.

Eli Lilly reports new data showing sustained efficacy for Ebglyss with less frequent dosing and strong long-term results for Olumiant in hair regrowth.

Lilly (LLY) to acquire Adverum Biotechnologies (ADVM) for $12.47 per share, with potential CVR payments tied to future milestones.